Further investigation on the tumor immune microenvironment with the IGRPM indicated that low-risk patients had a higher ImmuneScore and possessed a larger amount of activated TICs, such as CD8+ T cells, activated CD4+ memory T cells, and macrophages M1. The gene discussed is CD8A; the disease is neoplasm.